Back to search

Iceland· IS-EU/1/16/1110/001

Chenodeoxycholic acid Leadiant

A chenodeoxycholic acid product containing acidum chenodeoxycholicum inn, registered in Iceland by Leadiant GmbH. The same ATC class is registered in 12 of our 19 countries.

ATC A05AA01

Checked against Icelandic Medicines Agency (Iceland) on

Informational only — not a medical device.

SOURCE REGISTER · ISIcelandic Medicines Agency (Iceland)normalisedChenodeoxycholic acid LeadiantATCA05AA01REGISTER NO.IS-EU/1/16/1110/001PACKS LISTED0CHECKEDSeptember 29, 2026

Where it is registered

Chenodeoxycholic acid is registered in 12 of 19 countries.

Countries holding a registration under ATC A05AA01 (chenodeoxycholic acid), each read from that country’s own register.

  • This record: Iceland, from Icelandic Medicines Agency (Iceland)
  • 7 of them publish a price we can compare per daily dose

Chenodeoxycholic acid · ATC A05AA01

12 / 19 countries

  • Belgiumprice
  • Czechiaprice
  • Denmark
  • Finlandprice
  • Icelandprice
  • Ireland
  • Japan
  • Netherlands
  • Norwayprice
  • Polandprice
  • Switzerlandprice
  • United Kingdom
Blue: a registration under this ATC code. The ringed marker is this record’s country. Markets marked price publish a price we can compare per daily dose.

The record

At a glance

Icelandic Medicines Agency (Iceland)
Active substance
Acidum chenodeoxycholicum INN
Manufacturer
Leadiant GmbH
Country
Iceland (IS)
ATC code
A05AA01
ATC class
Chenodeoxycholic acid
Defined daily dose
1 g, O
Reimbursed
Not published by this register
Source register
Icelandic Medicines Agency (Iceland)
Last checked
September 29, 2026

Packs & prices · 0

No packs listed by the register for this record.

Regulatory notes

No shortage, Orange Book or US label notes for this record.

Interactions

57 interactions on record for chenodeoxycholic acid.

Graded by severity as the source publishes them — 7 severe. Severity grades are free for everyone; mechanism and management come with Growth.

  • Severity for every pair — free, no plan needed
  • The source, licence and sync date on every record
  • Mechanism and what to do for each pair — Growth plan

Chenodeoxycholic acid · interactions on record

57 records

  • 7 severe
  • 50 moderate

Most severe, free to view

  • MipomersenC10AX11severe
  • LomitapideC10AX12severe
  • PexidartinibL01EX15severe
  • LeflunomidL04AA13severe
  • Interaction severity from DDInter 2.0 (Xiong G. et al., Nucleic Acids Res.), licensed CC BY-NC 4.0 — free for non-commercial use only; not covered by the Drug Database commercial licence.
Mechanism and what to do, in the interaction check
Source: DDInter 2.0 · synced 29 Sept 2026. Grades as the source publishes them.

Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of Icelandic Medicines Agency (Iceland). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.

For developers

The same record over the API, and the raw payload
GET /v1/drugs/632ad258-e995-446f-9fce-03956702889c
GET /v1/drugs/632ad258-e995-446f-9fce-03956702889c?format=fhir

Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.

{
  "form": "Hart hylki",
  "source": "lyfjastofnun",
  "atc_raw": "A05AA01",
  "marketed": false,
  "strength": "250 mg",
  "ma_number": "EU/1/16/1110/001",
  "substance": "Acidum chenodeoxycholicum INN",
  "other_info": "Ávísun lyfsins er bundin við sérfræðinga í meltingarlækningum og sérfræðinga í innkirtla- og efnaskiptalækningum auk barnalækna með sérfræðiþekkingu í þessum greinum.",
  "legal_status": "(R Z) Sérfræðingsmerkt (og lyfseðilsskylt)",
  "ma_issued_serial": "42835"
}

See everything about chenodeoxycholic acid.

This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.